Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22607800 | 0.80 | ERN1 (0.54) | SMN1; SMN2HPGDALDH1A1LMNARAB9A | |
| SCHEMBL4244705 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL1336717 | 0.76 | CDK4 (0.49) | SMN1; SMN2MAPTALDH1A1LMNARAB9A | |
| SCHEMBL4908543 | 0.76 | ESR1 (0.41) | SMN1; SMN2MAPTRAB9AKMT2ANPC1 | |
| SCHEMBL1335295 | 0.76 | RAB9A (0.44) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL7251623 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL4246815 | 0.72 | PTGS2 (0.47) | SMN1; SMN2ALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL1335905 | 0.72 | XDH (0.39) | SMN1; SMN2MAPTALDH1A1LMNARAB9A | |
| SCHEMBL1335198 | 0.72 | PTGS2 (0.45) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL9609808 | 0.71 | SMN1; SMN2 (0.82) | SMN1; SMN2MAPTHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | SMN1; SMN2 3497/4885MAPT 3880/4885HPGD 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.